Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
Document › Details
Selexis S.A.. (3/7/18). "Press Release: Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics". Geneva.
Selexis SUREtechnology Platform™ in use for the generation of high-performance research cell banks for Compugen
Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today that Compugen Ltd. has taken a license to the Selexis SUREtechnology Platform™ for use in generating high-performance research cell banks (RCBs). A leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, Compugen will leverage Selexis’ mammalian cell line-based protein expression platform to develop antibody-based therapeutics targeting certain cancers, including to support further advancement of COM701.
Compugen’s lead immuno-oncology product candidate, COM701, is a humanized hybridoma antibody that binds with high affinity to PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen, blocking its interaction with PVRL2. The candidate is currently in preclinical development with an investigational new drug (IND) application filing with the U.S. Food and Drug Administration expected towards the end of the first quarter of 2018.
“Our agreement with Compugen is indicative of Selexis’ strength in protein expression and our leadership in bringing an innovative technology solution to our partners,” said Yemi Onakunle, PhD, Selexis vice president, business development and licensing. “It is rewarding for us to play a role in the important research and development efforts ongoing at Compugen and we value the opportunity to continue to play a role in enabling our partners to bring much needed treatment options to patients.”
“The Selexis SUREtechnology Platform enabled us to quickly generate a high-expressing cell line to support COM701 development activities,” said John Hunter, PhD, Compugen vice president of antibody R&D. “We look forward to working with the Selexis team as we advance future programs into the clinic.”
Selexis’ proprietary and high performance SUREtechnology Platform facilitates the rapid, stable and cost-effective production of virtually any recombinant protein including those that are difficult to express in other systems. It also provides seamless integration of the biologics and vaccine development continuum, spanning discovery to commercialization.
About Selexis SA
Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 95 drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.
###
FOR MORE INFORMATION
– Web www.selexis.com
– LinkedIn www.linkedin.com/company/selexis-sa
– Twitter www.twitter.com/SelexisSA
– Facebook www.facebook.com/SelexisSA
Media Inquiries for Selexis
Mike Beyer
Sam Brown Inc.
+1 312-961-2502
mikebeyer@sambrown.com
Company Inquiries for Selexis
Robert Meister
Head, Corporate Communications
+1 602-953-1716
robert.meister@selexis.com
Record changed: 2018-12-08 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for JSR Corporation (Group)
- [1] Selexis S.A.. (6/20/19). "Press Release: Avacta and Selexis Partner to Develop Cell Line for Clinical Manufacturing". Cambridge & Geneva....
- [2] Selexis S.A.. (3/28/19). "Press Release: Selexis Bolsters Business Development Team to Support Expanding Base of Partners Relying on Its SUREtechnology to Advance Complex Biologics and Vaccines". Geneva....
- [3] Selexis S.A.. (1/9/19). "Press Release: Selexis Expands Strategic Immuno-Oncology Alliance with Agenus". Geneva....
- [4] Selexis S.A.. (1/4/19). "Press Release: Selexis SA to Participate at Several Upcoming Industry Conferences". Geneva....
- [5] Selexis S.A.. (12/17/18). "Press Release: TeneoBio and Selexis Enter Second Services Agreement to Develop Research Cell Banks". Geneva & Menlo Park, CA....
- [6] Selexis S.A.. (12/3/18). "Press Release: KBI Biopharma Inc. and Selexis SA Form Joint Scientific Advisory Board". Durham, NC & Geneva....
- [7] Selexis S.A.. (10/18/18). "Press Release: Selexis and Berkeley Lights Collaborate to Accelerate Cell Line Development with the Beacon Optofluidic Platform". Geneva....
- [8] CytoSen Therapeutics, Inc.. (10/2/18). "Press Release: CytoSen Therapeutics and KBI Biopharma Enter into Strategic Partnership to Manufacture NK Cells and Nanoparticles". Dallas, TX & Durham, NC....
- [9] Selexis S.A.. (2/26/18). "Press Release: Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates". Geneva....
- [10] BiomX Ltd.. (1/29/18). "Press Release: BiomX Licenses Novel Bacterial Targets for the Treatment of IBD". Ness Ziona....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top